𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterization of SSEA-1 glycolipids from the brain of a patient with fucosidosis

✍ Scribed by Gerald A Schwarting; Marcia A Williams; James E Evans; Robert H McCluer

Publisher
Springer US
Year
1989
Tongue
English
Weight
759 KB
Volume
6
Category
Article
ISSN
1573-4986

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Adenovirus mixture isolated from the bra
Adenovirus mixture isolated from the brain of an AIDS patient with encephalitis
✍ David Schnurr; Andrew Bollen; Leta Crawford-Miksza; Marge E. Dondero; Shigeo Yag πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 376 KB

## Abstract A mixture of adenoviruses 31 and 49 was isolated from the brain of an AIDS patient with encephalitis. Adenovirus hexon protein was detected in neurons by indirect immunoflourescence. By restriction endonuclease analysis both adenovirus 31 and 49 were shown to be new genotypes. This is t

Molecular characterization of a ring chr
Molecular characterization of a ring chromosome 16 from a patient with bilateral cataracts
✍ He, Weigong ;Tuck-Muller, Cathy M. ;MartΓ­nez, JosΓ© E. ;Li, Shibo ;Rowley, Ewello πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 246 KB πŸ‘ 2 views

## Abstract A four‐month‐old white female, who was referred to us for genetic evaluation because of severe developmental delay, dysmorphic features, and bilateral cataracts, was found by routine cytogenetic analysis to have ring chromosome 16 in almost all cells analyzed. Ring chromosome 16 was con

Characterization of HIV-1 from patients
Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen
✍ Marie Rathcke Lillemark; Jan Gerstoft; Niels Obel; Gitte Kronborg; Court Pederse πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 122 KB

## Abstract The use of highly active antiretroviral treatment (HAART) regimens with unboosted protease inhibitors (PIs) has resulted in a high level of virological failure primarily due to the development of resistant virus. Current boosted PI regimens combine successfully low‐dose ritonavir (r) wi